The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Age: 2 - 17 years
Gender: All
We've found 5 total results for "Arthritis Psoriatic".
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Age: 2 - 17 years
Gender: All
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.T...
Age: 18 years - 66+
Gender: All
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Age: 18 years - 66+
Gender: All
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Age: 18 years - 66+
Gender: All
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will tr...
Age: 18 - 99 years
Gender: All